Select Publications
Conference Abstracts
2022, 'Substituting the world's salt supply', in Journal of Hypertension, Lippincott, Williams & Wilkins, JAPAN, Kyoto, Vol. 41, pp. E119 - E119, presented at 29th Scientific Meeting of the International Society of Hypertension (ISH), JAPAN, Kyoto, 12 October 2022 - 16 October 2022, http://dx.doi.org/10.1097/01.hjh.0000913896.40673.c0
,2022, 'CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL', in NEPHROLOGY, WILEY, Vol. 27, pp. 15 - 15, http://dx.doi.org/10.26190/unsworks/28407
,2022, 'Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney outcome guided by HbA(1c) and predicted risk of kidney failure', in DIABETOLOGIA, SPRINGER, SWEDEN, Stockholm, Vol. 65, pp. S278 - S278, presented at 58th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SWEDEN, Stockholm, 19 September 2022 - 23 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000841795900548&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Novel subgroups of patients with type 2 diabetes show differential cardiovascular and kidney benefits with canagliflozin: a data-driven proteomic cluster analysis', in DIABETOLOGIA, SPRINGER, SWEDEN, Stockholm, Vol. 65, pp. S132 - S132, presented at 58th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SWEDEN, Stockholm, 19 September 2022 - 23 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000841795900252&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'The effect of salt substitution on headache: a cluster-randomized controlled trial', in CEPHALALGIA, SAGE PUBLICATIONS LTD, Vol. 42, pp. 61 - 62, http://dx.doi.org/10.26190/unsworks/28462
,2022, 'EFFECTS OF SALT SUBSTITUTES ON BLOOD PRESSURE AND CLINICAL OUTCOMES IN DIFFERENT POPULATION GROUPS: A SYSTEMATIC REVIEW AND META-ANALYSIS', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, Vol. 79, pp. 1454 - 1454, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000781026601553&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Estimated Benefits And Risks Of Lowering Sodium Through Potassium-enriched Salt Substitution In India: A Modeling Study', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, Vol. 145, http://dx.doi.org/10.1161/circ.145.suppl_1.019
,2021, 'Heart failure therapies for the prevention of HER2-monoclonal antibody-mediated cardiotoxicity: A systematic review and meta-analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 119 - 119, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'The Impact of Australasian Voluntary Front of Pack Nutrition Labelling on Packaged Food Reformulation', in INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, OXFORD UNIV PRESS, Vol. 50, pp. 21 - 21, http://dx.doi.org/10.1093/ije/dyab168.050
,2021, 'The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial', in Diabetes, Obesity and Metabolism, Vol. 23, pp. 1652 - 1659, http://dx.doi.org/10.1111/dom.14386
,2021, 'Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus', in Metabolism, Elsevier, Vol. 116, pp. 154509, http://dx.doi.org/10.1016/j.metabol.2020.154509
,2021, 'HOW MANY ADDITIONAL PHYSICIANS ARE NEEDED FOR HYPERTENSION TREATMENT IN INDIA?', in Journal of Hypertension, Wolters Kluwer, Vol. 39, pp. e85, http://dx.doi.org/10.1097/01.hjh.0000745236.87471.17
,2020, 'Acute declines in eGFR during treatment with canagliflozin and its implications for clinical practice: insights from CREDENCE', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S269 - S269, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000565776600560&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S61 - S62, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, http://dx.doi.org/10.26190/unsworks/27933
,2020, 'Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 41, pp. 1175 - 1175, presented at European-Society-of-Cardiology (ESC) Congress, ELECTR NETWORK, 29 August 2020 - 01 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606106301178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial', in DIABETES, AMER DIABETES ASSOC, ELECTR NETWORK, Vol. 69, presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-1120-P
,2020, 'Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial', in DIABETES, AMER DIABETES ASSOC, ELECTR NETWORK, Vol. 69, presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-1098-P
,2020, 'CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1336 - 1336, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000562392101381&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1342 - 1342, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000562392101387&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1351 - 1351, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, http://dx.doi.org/10.1093/ndt/gfaa142|iii1351
,2020, 'Contribution of Major Food Companies and Their Products to Household Dietary Sodium Purchases in Australia', in Current Developments in Nutrition, Oxford University Press (OUP), presented at American Society of Nutrition 2020, http://dx.doi.org/10.1093/cdn/nzaa067_017
,2020, 'CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 75, pp. 1018 - 1018, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), IL, Chicago, 28 March 2020 - 30 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000522979101006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 75, pp. 1852 - 1852, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), IL, Chicago, 28 March 2020 - 30 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000522979101839&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 75, pp. 215 - 215, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), IL, Chicago, 28 March 2020 - 30 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000522979100211&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'An exploration of factors mediating the effects of canagliflozin on heart failure in patients with type 2 diabetes', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S343 - S343, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303803044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Canagliflozin in patients with type 2 diabetes and macroalbuminuria: data from the CANVAS program', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S341 - S342, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303803041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'The effects of canagliflozin on uric acid and gout in patients with type 2 diabetes in the CANVAS programme', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S340 - S341, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303803039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'DIFFERENT EGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, HUNGARY, Budapest, Vol. 34, pp. 206 - 206, presented at 56th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA) - Burden, Access and Disparities in Kidney Disease, HUNGARY, Budapest, 13 June 2019 - 16 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000495412900569&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Abstract P294: Estimated Benefits and Risks of Lowering Sodium Intake With Potassium-based Salt Substitutes in China: a Modelling Study', in Circulation, Wolters Kluwer, TX, Houston, Vol. 139, presented at Scientific Sessions of the American-Heart-Association on Epidemiology and Prevention/Lifestyle and Cardiometabolic Health, TX, Houston, 05 March 2019 - 08 March 2019, http://dx.doi.org/10.1161/circ.139.suppl_1.p294
,2019, 'Benefits and Risks of Lowering Sodium Through Potassium-enriched Salt Substitution for Patients with Chronic Kidney Disease in China: A Modelling Study (OR25-05-19).', in Curr Dev Nutr, United States, Vol. 3, United States, http://dx.doi.org/10.1093/cdn/nzz051.OR25-05-19
,2018, 'IMPACT OF DIETARY SODIUM REDUCTION ON ESTIMATED GLOMERULAR FILTRATION RATE IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS', in NEPHROLOGY, WILEY, Vol. 23, pp. 43 - 43, presented at Australian and New Zealand Society of Nephrology., http://dx.doi.org/10.26190/unsworks/28692
,2018, 'CANAGLIFLOZIN AND RENAL OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE', in AMERICAN JOURNAL OF KIDNEY DISEASES, W B SAUNDERS CO-ELSEVIER INC, TX, Austin, Vol. 71, pp. 574 - 574, presented at Spring Clinical Meeting of the National-Kidney Foundation (NKD), TX, Austin, 10 April 2018 - 14 April 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000428167100243&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Blood pressure reduction and stroke recurrence: the PROGRESS trial', in CEREBROVASCULAR DISEASES, KARGER, Vol. 35, pp. 124 - 124, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329092600170&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, '434 EARLIER BLOOD PRESSURE LOWERING AND GREATER ATTENUATION OF HAEMATOMA GROWTH IN ACUTE INTRACEREBRAL HAEMORRHAGE', in Journal of Hypertension, Ovid Technologies (Wolters Kluwer Health), Vol. 30, pp. e129 - e129, http://dx.doi.org/10.1097/01.hjh.0000420289.21412.53
,2011, 'EFFECTS OF BLOOD PRESSURE LOWERING ON INTRACRANIAL AND EXTRACRANIAL BLEEDING ASSOCIATED WITH ANTITHROMBOTIC THERAPY: THE PROGRESS TRIAL', in HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, AUSTRALIA, Perth, Vol. 60, pp. 499 - 499, presented at 33rd Annual Scientific Meeting of the High-Blood-Pressure-Research-Council-of-Australia (HBPRCA), AUSTRALIA, Perth, 06 December 2011 - 09 December 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000306550900095&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'EFFECTS OF PERINDOPRIL-BASED BLOOD PRESSURE LOWERING AMONG PATIENTS WITH ISOLATED DIASTOLIC HYPERTENSION AND PRIOR CEREBROVASCULAR DISEASE: THE PROGRESS TRIAL', in HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, AUSTRALIA, Melbourne, Vol. 58, pp. 122 - 122, presented at 32nd Annual Scientific Meeting of the High Blood Pressure Research Council of Australia, AUSTRALIA, Melbourne, 01 December 2010 - 03 December 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000291655000056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'EFFECTS OF THE ENDPOINT ADJUDICATION PROCESS ON THE RESULTS OF THE CLINICAL TRIAL: THE ADVANCE STUDY', in HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, AUSTRALIA, Melbourne, Vol. 58, pp. 118 - 118, presented at 32nd Annual Scientific Meeting of the High Blood Pressure Research Council of Australia, AUSTRALIA, Melbourne, 01 December 2010 - 03 December 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000291655000036&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2006, 'Lower target blood pressures are safe and effective for the prevention of recurrent stroke: The progress trial', in JOURNAL OF HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, JAPAN, Fukuoka, Vol. 24, pp. 141 - 141, presented at 21sth Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension, JAPAN, Fukuoka, 15 October 2006 - 19 October 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000242774001002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2005, 'Amino-terminal pro-B-type natriuretic peptide (NT-proBNP): a risk factor for most seasons', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, SWEDEN, Stockholm, Vol. 26, pp. 257 - 257, presented at 27th Congress of the European-Society-of-Cardiology, SWEDEN, Stockholm, 03 September 2005 - 07 September 2005, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000233987101471&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2004, 'Amino-terminal pro-brain-type natriuretic peptide and C-reactive protein predict development of heart failure in subjects with cerebrovascular disease', in EUROPEAN HEART JOURNAL, W B SAUNDERS CO LTD, GERMANY, Munich, Vol. 25, pp. 290 - 290, presented at ESC Congress 2004, GERMANY, Munich, 28 August 2004 - 01 September 2004, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000224056501157&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2002, 'Cardiac outcomes in the perindopril protection against recurrent stroke study (PROGRESS)', in JOURNAL OF HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, CZECH REPUBLIC, PRAGUE, Vol. 20, pp. S169 - S169, presented at 19th Meeting of the International-Society-for-Hypertension/12th European-Society-of-Hypertension Meeting, CZECH REPUBLIC, PRAGUE, 23 June 2002 - 27 June 2002, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000178386300785&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2002, 'Progress in dementia and cognitive function in stroke patients', in JOURNAL OF HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, CZECH REPUBLIC, PRAGUE, Vol. 20, pp. S339 - S339, presented at 19th Meeting of the International-Society-for-Hypertension/12th European-Society-of-Hypertension Meeting, CZECH REPUBLIC, PRAGUE, 23 June 2002 - 27 June 2002, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000178386301559&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,